Acute chest pain (ACP) is a prevalent symptom in clinical practice, often indicative of potentially life-threatening conditions such as acute coronary syndrome (ACS) or pulmonary embolism. However, it may also stem from benign causes, necessitating a careful and systematic diagnostic approach.
ACP evaluation commences with a thorough history and physical examination. The aim is to identify high-risk features suggestive of ACS, including pain characteristics, associated symptoms, risk factors, and prior cardiac history. Concurrently, vital signs and physical findings can hint at alternative diagnoses, like aortic dissection or pericarditis.
Electrocardiogram (ECG) is the first-line diagnostic test, performed promptly to detect ST-segment elevation myocardial infarction (STEMI). Non-diagnostic ECGs do not exclude ACS and warrant further testing. Cardiac biomarkers, primarily high-sensitivity troponins, are invaluable in ACS diagnosis, with serial measurements recommended in the first 3 hours from symptom onset.
Chest X-ray, while typically normal in ACS, can reveal alternative diagnoses like pneumonia or pneumothorax. Computed tomography (CT) angiography is the imaging modality of choice for suspected pulmonary embolism or aortic dissection. Coronary CT angiography can also be used in low-risk patients to rule out coronary artery disease.
Risk stratification tools, such as the HEART score, guide further management. Low-risk patients might undergo stress testing or advanced imaging, while high-risk patients require hospitalization and invasive strategies.
ACP presents a diagnostic challenge, necessitating a systematic approach to distinguish serious from benign causes. A comprehensive history and physical examination, combined with judicious use of diagnostic tests and risk stratification tools, are pivotal in guiding management and improving patient outcomes. Continued research and technological advancements promise to refine this process further, enhancing our ability to accurately diagnose and treat this common clinical presentation.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation